Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zileuton - Qurient

Next Previous
Search
Drug Profile

Zileuton - Qurient

Alternative Names: Q-301; Topical 5LO Inhibitor - Qurient

Latest Information Update: 01 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qurient Co
  • Class Antiasthmatics; Skin disorder therapies; Small molecules; Urea compounds
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 09 Mar 2021 Q 301 is still in phase II trials for Atopic dermatitis in USA (Topical) (Qurient pipeline, March 2021)
  • 21 Apr 2020 Qurient completes a phase II trial in Atopic dermatitis (In adolescents, In adults) in USA (Topical) (NCT03571620)
  • 27 Jun 2019 Efficacy and adverse events data from phase IIa trial in Atopic dematitis were presented at the 77th Annual Meeting of the American Academy of Dermatology (AAD-2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top